IMCR
Immunocore Holdings plc NASDAQ Listed Feb 5, 2021$30.69
Mkt Cap $1.6B
52w Low $27.44
24.5% of range
52w High $40.72
50d MA $30.78
200d MA $33.39
P/E (TTM)
-53.1x
EV/EBITDA
3417.9x
P/B
3.7x
Debt/Equity
0.1x
ROE
-9.3%
P/FCF
-156.1x
RSI (14)
—
ATR (14)
—
Beta
0.83
50d MA
$30.78
200d MA
$33.39
Avg Volume
420.2K
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
92 Park Drive · Abingdon, X0 OX14 4RY · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | -0.28 | -0.60 | -114.3% | 32.16 | -0.9% | -0.4% | +0.8% | +1.1% | -0.9% | +4.2% | — |
| Nov 6, 2025 | BMO | -0.30 | 0.02 | +105.2% | 31.60 | +0.2% | +6.0% | +4.5% | +0.6% | +0.3% | +0.2% | — |
| Aug 7, 2025 | BMO | -0.21 | -0.20 | +4.8% | 31.93 | +0.7% | +0.1% | -0.3% | -0.1% | +3.5% | +0.2% | — |
| May 7, 2025 | BMO | -0.35 | 0.10 | +128.6% | 29.92 | +0.1% | -0.4% | -4.7% | +4.0% | -3.4% | -3.0% | — |
| Feb 26, 2025 | BMO | -0.31 | -0.47 | -51.6% | 30.77 | -2.6% | -3.9% | -0.7% | -1.7% | +1.3% | +3.4% | — |
| Nov 6, 2024 | BMO | -0.35 | 0.17 | +148.6% | 33.51 | +1.8% | +2.4% | +1.1% | -0.1% | -2.6% | +1.2% | — |
| Aug 8, 2024 | BMO | -0.45 | -0.23 | +48.9% | 37.92 | +1.3% | -1.9% | +1.2% | -0.2% | -1.5% | -0.6% | — |
| May 8, 2024 | BMO | -0.33 | -0.49 | -48.5% | 61.32 | -0.8% | -2.4% | -1.5% | -3.3% | -2.0% | +0.3% | — |
| Feb 28, 2024 | BMO | -0.28 | -0.40 | -42.9% | 69.21 | +2.9% | -2.9% | +0.3% | -3.0% | -0.5% | -1.7% | — |
| Nov 7, 2023 | BMO | -0.32 | 0.04 | +112.5% | 50.71 | +0.6% | +2.4% | -5.9% | +2.7% | -0.3% | -2.1% | — |
| Aug 10, 2023 | BMO | -0.40 | -0.37 | +7.5% | 61.66 | +0.9% | +0.4% | -1.9% | -0.7% | -0.9% | -2.3% | — |
| May 10, 2023 | BMO | -0.30 | -0.43 | -43.3% | 59.86 | +0.6% | -1.7% | +4.4% | +0.3% | -4.8% | -4.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.45 | $31.51 | +0.2% | +0.0% | -6.2% | +1.6% | -2.5% | +0.2% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.47 | $31.44 | -0.1% | +0.7% | -0.2% | -0.8% | +0.2% | +0.0% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $30.86 | $30.36 | -1.6% | -0.9% | +0.5% | -2.2% | +0.0% | -0.4% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $32.16 | $31.87 | -0.9% | -0.4% | +0.8% | +1.1% | -0.9% | +4.2% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.07 | $32.19 | +0.4% | -1.8% | -1.8% | +3.4% | +4.0% | -1.3% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $33.50 | $33.94 | +1.3% | +4.5% | +0.6% | +0.3% | +0.2% | +1.6% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.57 | $33.39 | -0.5% | -3.2% | -2.8% | +4.7% | +1.1% | +0.9% |
| Jun 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.60 | $37.03 | +1.2% | +5.6% | -0.0% | -2.4% | +0.8% | -2.0% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.92 | $29.96 | +0.1% | -0.4% | -4.7% | +4.0% | -3.4% | -3.0% |
| Apr 14 | JP Morgan | Maintains | Overweight → Overweight | — | $26.59 | $27.16 | +2.1% | +1.2% | +1.4% | +2.1% | +1.9% | +3.5% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $26.12 | $26.00 | -0.5% | -1.1% | +3.0% | +1.2% | +1.4% | +2.1% |
| Apr 7 | Mizuho | Maintains | Neutral → Neutral | — | $27.26 | $25.84 | -5.2% | -3.6% | -6.7% | +6.5% | -1.1% | +3.0% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $28.42 | $28.44 | +0.1% | +2.2% | -2.7% | +1.9% | +4.3% | -5.5% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.42 | $28.44 | +0.1% | +2.2% | -2.7% | +1.9% | +4.3% | -5.5% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.25 | $29.40 | +0.5% | +3.4% | +1.9% | -3.3% | -2.7% | -2.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.58 | $29.66 | +0.3% | -0.7% | -1.7% | +1.3% | +3.4% | +1.9% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $30.77 | $29.97 | -2.6% | -3.9% | -0.7% | -1.7% | +1.3% | +3.4% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.00 | $32.52 | -1.5% | -2.2% | -0.6% | -1.4% | +3.1% | +0.8% |
| Jan 10 | Needham | Maintains | Buy → Buy | — | $30.23 | $29.48 | -2.5% | +0.6% | -1.2% | -4.9% | +3.1% | -1.2% |
| Dec 13 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $30.31 | $29.03 | -4.2% | -4.6% | +1.5% | +0.2% | -3.9% | +0.6% |
| Nov 11 | Mizuho | Downgrade | Outperform → Neutral | — | $34.69 | $33.61 | -3.1% | -0.1% | -2.6% | +1.2% | -4.5% | -3.2% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $33.51 | $34.11 | +1.8% | +2.4% | +1.1% | -0.1% | -2.6% | +1.2% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.02 | $31.27 | -2.3% | +1.5% | +0.9% | +1.6% | -1.9% | -2.4% |
| Oct 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.89 | $30.99 | +0.3% | +0.6% | +3.5% | +0.4% | +2.9% | +1.4% |
| Oct 7 | Guggenheim | Downgrade | Buy → Neutral | — | $31.11 | $30.57 | -1.7% | -1.2% | -0.6% | -1.9% | +3.0% | +0.6% |
| Sep 17 | Needham | Maintains | Buy → Buy | — | $33.00 | $33.30 | +0.9% | +2.7% | +1.6% | -0.7% | -3.0% | -7.2% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.00 | $33.30 | +0.9% | +2.7% | +1.6% | -0.7% | -3.0% | -7.2% |
| Aug 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.15 | $36.00 | -0.4% | -0.0% | -4.2% | +3.6% | +0.6% | +0.7% |
| Aug 9 | Barclays | Maintains | Overweight → Overweight | — | $37.92 | $38.42 | +1.3% | -1.9% | +1.2% | -0.2% | -1.5% | -0.6% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $37.92 | $38.42 | +1.3% | -1.9% | +1.2% | -0.2% | -1.5% | -0.6% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $37.92 | $38.42 | +1.3% | -1.9% | +1.2% | -0.2% | -1.5% | -0.6% |
| Jul 10 | JP Morgan | Maintains | Overweight → Overweight | — | $38.29 | $38.87 | +1.5% | -0.7% | +3.6% | +0.3% | -0.1% | +5.1% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.31 | $43.12 | -0.4% | -0.6% | -0.8% | -2.4% | -3.0% | +1.6% |
| Jun 3 | Needham | Maintains | Buy → Buy | — | $48.98 | $48.41 | -1.2% | -12.7% | +1.3% | -0.6% | -0.8% | -2.4% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.70 | $46.12 | +0.9% | +2.2% | +4.9% | -12.7% | +1.3% | -0.6% |
| May 29 | Needham | Maintains | Buy → Buy | — | $46.30 | $46.36 | +0.1% | -1.3% | +2.2% | +4.9% | -12.7% | +1.3% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.98 | $45.00 | -6.2% | -4.0% | +0.5% | -1.3% | +2.2% | +4.9% |
| May 24 | Needham | Maintains | Buy → Buy | — | $47.98 | $45.00 | -6.2% | -4.0% | +0.5% | -1.3% | +2.2% | +4.9% |
| May 13 | Mizuho | Maintains | Buy → Buy | — | $58.95 | $58.73 | -0.4% | -3.3% | -2.0% | +0.3% | -3.1% | -1.8% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.32 | $60.83 | -0.8% | -2.4% | -1.5% | -3.3% | -2.0% | +0.3% |
| May 9 | Canaccord Genuity | Maintains | Hold → Hold | — | $61.32 | $60.83 | -0.8% | -2.4% | -1.5% | -3.3% | -2.0% | +0.3% |
| May 9 | Needham | Maintains | Buy → Buy | — | $61.32 | $60.83 | -0.8% | -2.4% | -1.5% | -3.3% | -2.0% | +0.3% |
| Apr 23 | Guggenheim | Maintains | Buy → Buy | — | $55.82 | $56.40 | +1.0% | +2.7% | +2.0% | -0.8% | +0.8% | -0.6% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $58.81 | $59.15 | +0.6% | +0.4% | -4.3% | -1.8% | -3.9% | +2.3% |
| Mar 20 | JP Morgan | Maintains | Overweight → Overweight | — | $61.61 | $62.00 | +0.6% | +2.1% | -1.6% | +2.6% | -1.6% | -1.4% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.06 | $65.35 | +0.4% | -1.7% | -1.5% | -2.3% | -1.1% | +0.4% |
| Mar 5 | Mizuho | Maintains | Buy → Buy | — | $65.37 | $65.37 | +0.0% | -0.5% | -1.7% | -1.5% | -2.3% | -1.1% |
| Feb 29 | Canaccord Genuity | Maintains | Hold → Hold | — | $69.21 | $71.19 | +2.9% | -2.9% | +0.3% | -3.0% | -0.5% | -1.7% |
| Feb 29 | Needham | Maintains | Buy → Buy | — | $69.21 | $71.19 | +2.9% | -2.9% | +0.3% | -3.0% | -0.5% | -1.7% |
| Feb 29 | Oppenheimer | Maintains | Outperform → Outperform | — | $69.21 | $71.19 | +2.9% | -2.9% | +0.3% | -3.0% | -0.5% | -1.7% |
No insider trades available.
8-K · 2.02
!! High
Immunocore Holdings plc -- 8-K 2.02: Earnings Results
Immunocore Holdings announced Q1 2026 earnings results and corporate updates on May 6, 2026, though specific financial metrics and guidance changes were not disclosed in this filing summary.
May 6
8-K
Immunocore Holdings plc -- 8-K Filing
Immunocore Holdings reported full-year 2025 financial results, with the commercial-stage biotech disclosing fourth-quarter and year-end performance metrics for its immunomodulating medicine pipeline.
Feb 25
Data updated apr 26, 2026 10:59am
· Source: massive.com